A group of cancer genetics researchers in Italy and the U.S. has retracted three papers in the Journal of Biological Chemistry (JBC) after it became aware they had duplicated some bands in their figures.
Here are the three papers: Continue reading Cancer genetics group retracts three papers for “inappropriate presentation of data”
A group of authors in China has lost their 2011 paper in Bioresource Technology on pig poop because the journal detected a whiff of the familiar in a previously published article by other researchers in the same journal (a major tsk tsk and, well, oops).
The article, “Feasibility of biogas production from anaerobic co-digestion of herbal-extraction residues with swine manure,” came from a team at Nanchang University. Except, well, not really, as we’ll see. According to its abstract:
Continue reading If it smells like pig sh@#, it probably is pig sh@#: A stinky retraction
Radical geography journal Antipode has retracted a paper on sexuality and geography after discovering that author Martin Zebracki published an almost identical article in a Dutch magazine on which he served as a member of the editorial board.
Here’s the retraction notice for “Right to Space: Moving Towards Sexual Citizenship Beyond the Nation State”: Continue reading Radical geographer doubles up on sexuality paper, earns retraction
The Journal of Biomedicine and Biotechnology — now BioMed Research International — has retracted a 2012 paper by a group from China who seem really to have admired a related 2007 article by a team from the Scripps Research Institute — and evidently other work, as well.
Here’s the abstract of the now-retracted paper, titled “Stable Plastid Transformation for High-Level Recombinant Protein Expression: Promises and Challenges” (emphasis ours): Continue reading Recombinant protein paper retracted for recombining others’ work
BioMed Research International has retracted a 2013 paper after it became clear that it was lifted from another 2013 paper about the same subject by some of the same authors.
According to the retraction notice: Continue reading Duplication forces retraction of liver cancer paper
The journal Blood has retracted a 2010 paper over the objections of most of its authors, two of whom were found by their university to have used “fraudulent methods” to obtain the data.
We first reported on the case of Gerold Feuer last fall. The State University of New York (SUNY) Upstate Medical Center in Syracuse fired Feuer in 2010 after determining that he had misused state funds to enrich a company he had founded, HuMurine. A court agreed with many of the university’s claims, but ordered his reinstatement in 2012.
Meanwhile, as we noted last fall: Continue reading Journal retracts stem cell study despite objections of most authors
Karel Bezouška, the scientist who tried to derail an investigation into his work by breaking into a lab refrigerator has had an eighth paper retracted.
Here’s the notice for “Synthetic N-Acetyl-d-glucosamine Based Fully Branched Tetrasaccharide, a Mimetic of the Endogenous Ligand for CD69, Activates CD69+ Killer Lymphocytes upon Dimerization via a Hydrophilic Flexible Linker:” Continue reading Researcher who tampered with investigation up to 8 retractions
Earlier this month, we brought you the story of a retraction from the Journal of the Association for Information Science and Technology involving rivalry and alleged sock puppetry. The author of the now-retracted letter, physicist Lorenzo Iorio, claimed that another researcher was using fake names to criticize his work on arXiv.At the time, the editor of the journal had told everyone concerned that the letter would be retracted, but the retraction notice hadn’t yet appeared. Now it has.
Here’s the notice: Continue reading Retraction of letter alleging sock puppetry now cites “legal reasons”
The pixels were barely dry on our post reporting the 14th and 15th retractions for management professor Ulrich Lichtenthaler Friday by the time his 16th retraction appeared.
Here’s the notice for “The role of deliberate and experiential learning in developing capabilities: Insights from technology licensing,” a paper originally published in 2012 in the Journal of Engineering and Technology Management: Continue reading Ulrich Lichtenthaler retraction count rises to 16
Pfizer has retracted another study involving an experimental cancer drug that later failed later-stage trials.
The study, published in Clinical Cancer Research in 2010, looked at which patients might respond to the drug, called figitumumab. Here’s the notice: Continue reading Pfizer retracts another experimental cancer drug study